[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353131-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353131-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ai-decision-support-for-increasing-prostate-biopsy-efficiency-a-retrospective-multicentre-multiscanner-study","AI decision support for increasing prostate biopsy efficiency - a retrospective multicentre, multiscanner study","","Artificial intelligence-based decision support is developed to optimize prostate biopsy decisions and improve benefit-to-harm ratios. A retrospective multicentre, multiscanner dataset of 1022 patients is used, with 770 cases for development and 252 men from six UK centres for independent validation. The AI-DSS integrates PI-RADS, automated PSA density, and deep-learning imaging risk scores, benchmarked against real-world clinical decisions using grade selectivity, biopsy efficiency, and selective biopsy avoidance outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ai-decision-support-for-increasing-prostate-biopsy-efficiency-a-retrospective-multicentre-multiscanner-study/353131/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ai-decision-support-for-increasing-prostate-biopsy-efficiency-a-retrospective-multicentre-multiscanner-study/353131.png","ImageObject",300,407,{"name":42,"@type":43},"Jasmine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the goal of the AI decision support system (AI-DSS)?","Question",{"text":63,"@type":64},"To optimize prostate biopsy decisions and improve the benefit-to-harm ratio by supporting more efficient biopsy selection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the AI-DSS developed and validated?",{"text":68,"@type":64},"It was developed on 770 cases and validated on an independent cohort of 252 men from six UK centres, using multicentre, multiscanner retrospective data.",{"name":70,"@type":61,"acceptedAnswer":71},"What improvements did the AI-DSS show in validation?",{"text":72,"@type":64},"At a 31% cancer detection rate, it would have avoided 28 biopsies while missing one ≥ GG2 cancer, increasing grade selectivity and biopsy efficiency and increasing selective biopsy avoidance versus the reference standard.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353131,1790552012,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":22,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Sushentsev et al. European Radiology (2026) 36:5719–5727  \n[https://doi.org/10.1007/s00330-026-12361-6](https://doi.org/10.1007/s00330-026-12361-6)  \nURO GENITAL Open Access  \nAI decision support for increasing prostate   biopsy efﬁciency: a retrospective  \nmulticentre, multiscanner study  \nNikita Sushentsev 1* , Zobair Arya2, Jobie Budd2, Amy Frary2, Nadia Moreira da Silva2, Mirjana Ferrer Rodriguez2, Paul Burn3, Richard Hindley4,5, Nikhil Vasdev6,7, Mohamed Ibrahim8, Alison Bradley9, Adrian Andreou 10, Sidath Liyanage 11, Raj Persad 12, Jonathan Aning 12, Alexander B. C. D. Ng 13,14, Aqua Asif13,14,  \nVeeru Kasivisvanathan 13,14,15, Tristan Barrett 1, Mark Hinton2, Anwar Roshanali Padhani 16, Aarti Shah5, Lucy Davies2, Antony Rix2 and Evis Sala 17,18  \nAbstract  \nObjectives To develop and retrospectively validate an artiﬁcial intelligence-based decision support system (AI-DSS) for optimising prostate biopsy decisions and improving beneﬁt-to-harm ratios.  \nMaterials and methods This retrospective, multicentre, multiscanner study used data from 1022 patients. An AI-DSS integrating PI-RADS scores, automated prostate-speciﬁc antigen density (PSAd), and deep-learning imaging risk scores was developed on 770 cases and validated on an independent cohort of 252 men from six UK centres. The AI-DSS performance was benchmarked against the real-world clinical decisions (reference standard) using grade selectivity, biopsy efﬁciency, and selective biopsy avoidance as outcome measures. Biopsy-proven detection of grade group (GG) ≥ 2 disease was the reference standard.  \nResults In the validation cohort of 252 patients (mean age, 67 . 3 years), 137 underwent biopsy and 79 (31%) harboured ≥ GG2 disease. Compared to the reference standard, the AI-DSS at the 31% cancer detection rate (CDR) would have avoided 28 biopsies while missing one ≥ GG2 cancer. This corresponded to a 70% increase in grade selectivity (from 4.6 to 7.8), 79% increase in biopsy efﬁciency (from 1.4 to 2.5), and a 143% increase in selective biopsy avoidance (from 2 . 8 to 6 . 8) . At the reduced CDR of 30%, grade selectivity, biopsy efﬁciency, and selective biopsy avoidance increased by 172%, 236%, and 475%, with four ≥ GG2 cancers missed.  \nConclusion An AI-DSS that integrates clinical and advanced imaging data improves the beneﬁt-to-harm ratio of prostate biopsy decisions in a retrospective setting. Future prospective validation as part of real-world clinical workﬂowis required to enable clinical implementation.  \nKey Points  \nQuestion Current prostate cancer diagnostic pathways result in fewer unnecessary biopsies. Can an AI decision support system (AI-DSS) further improve biopsy efﬁciency for detecting signiﬁcant cancer?  \n\n| Nikita Sushentsev, Zobair Arya and Jobie Budd contributed equally to this work. |\n| --- |\n| Lucy Davies, Antony Rix and Evis Sala jointly supervised this work. |\n\n*Correspondence: Nikita Sushentsev  \n[ns784@medschl.cam.ac.uk](ns784@medschl.cam.ac.uk)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026 . Open Access This article is licensed under a Creative Commons Attribution 4 . 0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/](http://creativecommons.org/)[ ](http://creativecommons.org/)[licenses/by/4.0/](lic","cbCaiaGAzqjcGGLb","https://ap.wps.com/l/cbCaiaGAzqjcGGLb","pdf",3809669,"English","# Abstract\n## Objectives\n## Materials and methods\n## Results\n## Conclusion\n# Key points\n# Introduction\n## mpMRI as first-line diagnostic tool\n## Limitations of current diagnostic pathway\n## Role of AI-based decision support","[{\"question\":\"What was the goal of the AI decision support system (AI-DSS)?\",\"answer\":\"To optimize prostate biopsy decisions and improve the benefit-to-harm ratio by supporting more efficient biopsy selection.\"},{\"question\":\"How was the AI-DSS developed and validated?\",\"answer\":\"It was developed on 770 cases and validated on an independent cohort of 252 men from six UK centres, using multicentre, multiscanner retrospective data.\"},{\"question\":\"What improvements did the AI-DSS show in validation?\",\"answer\":\"At a 31% cancer detection rate, it would have avoided 28 biopsies while missing one ≥ GG2 cancer, increasing grade selectivity and biopsy efficiency and increasing selective biopsy avoidance versus the reference standard.\"}]","AI decision support for increasing prostate biopsy efficiency - a retrospective multicentre, multiscanner study | PDF",1790103191,23,[147],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/42c85024639b4560460eef3d4784e3e3.webp",983,1306]